pembrolizumab for ps2 patients with adv. nsclc: results of the peps2 trial (bmic-067)
Published 5 years ago • 180 plays • Length 4:13Download video MP4
Download video MP3
Similar videos
-
2:21
spearhead-2 trial design: combining spear t-cells with pembrolizumab
-
11:05
keynote-042: should pembrolizumab replace chemo for broader population with adv. nsclc? (bmic-038)
-
6:16
keynote-189: clinical implications in patients with low (1-49%) tumor pd-l1 expression (bmic-032)
-
1:56
eftilagimod alpha and pembrolizumab in patients with squamous head and neck carcinoma
-
14:02
the role of bcl2 inhibitors in clonal hematopoiesis - dr. piers blombery ash 2023
-
4:23
all of the chemo! (gemcitabine 100%)
-
5:51
pembrolizumab is safe and effective and substantially increases overall survival in ansclc patients
-
15:57
10 feb 2022-spm-perkhidmatan dual diagnosis dan model i-pulih
-
6:32
keynote-189: clinical implications in patients with less than 1% tumor pd-l1 expression (bmic-033)
-
8:25
study of nab-paclitaxel with pembrolizumab for patients with hr /her2- breast cancer
-
3:01
pembrolizumab: new weapon in the fight against melanoma?
-
2:21
phase 2 study of pembrolizumab in patients with advanced rare cancers
-
8:57
nivo/ipi rx of choice for adv. nsclc, pd-l1 under 1%, high tmb? new checkmate 227 data (bmic-040)
-
5:16
pembrolizumab found to be safe with durable responses in advanced, non-small cell lung cancer
-
12:38
is chemo the key for egfr mutation-positive nsclc? the data too good to overlook (bmic-045)
-
2:09
pembrolizumab in patients with locally advanced bladder cancer
-
1:17
prince: 177lu-psma-617 and pembrolizumab in prostate cancer
-
4:42
pembrolizumab for patients with high-risk, non-muscle invasive bladder cancer
-
0:51
dr. balar on the approval of pembrolizumab for bladder cancer
-
3:22
can immunotherapy improve survival in relapsed nsclc patients?
-
1:14
dr. plimack on second-line checkpoint inhibitors in bladder cancer